A phase 3, randomized, open-label study of epacadostat plus pembrolizumab, pembrolizumab monotherapy, and the EXTREME regimen as first-line treatment for recurrent/metastatic head and neck squamous cell carcinoma (R/M SCCHN): ECHO-304/KEYNOTE-669 Meeting Abstract
| Authors: | Cohen, E. E. W.; Rischin, D.; Pfister, D. G.; Vermorken, J. B.; Zhao, Y.; Gowda, H.; Ge, J. Y.; Jin, F.; Harrington, K. J. |
| Abstract Title: | A phase 3, randomized, open-label study of epacadostat plus pembrolizumab, pembrolizumab monotherapy, and the EXTREME regimen as first-line treatment for recurrent/metastatic head and neck squamous cell carcinoma (R/M SCCHN): ECHO-304/KEYNOTE-669 |
| Meeting Title: | 54th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 36 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2018 Jun 1-5 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2018-05-20 |
| Start Page: | 344s |
| Language: | English |
| ACCESSION: | WOS:000442916007693 |
| DOI: | 10.1200/JCO.2018.36.15_suppl.TPS6090 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: TPS6090 -- Source: Wos |
